Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 56.53 |
| Open | 55.84 |
| Bid | 54.77 x 4000 |
| Ask | 54.82 x 1400 |
| Day's range | 54.60 - 56.30 |
| 52-week range | 54.60 - 69.75 |
| Volume | |
| Avg. volume | 11,429,175 |
| Market cap | 121.281B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.42 |
| Earnings date | 04 Feb 2022 |
| Forward dividend & yield | 1.96 (3.47%) |
| Ex-dividend date | 30 Sept 2021 |
| 1y target est | 73.12 |
- Zacks
Bristol Myers (BMY) Top Drugs Maintain Momentum Amid Competition
Bristol Myers' (BMY) performance has been good of late, driven by Revlimid, Eliquis, Opdivo and its new product portfolio amid stiff competition.
- Business Wire
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
PRINCETON, N.J., November 29, 2021--BMS's Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. FDA and Validated by EMA
- Motley Fool
3 Surefire Winning Stocks to Buy If There's a Stock Market Crash
Although crashes are inevitable, they're the perfect time to buy great businesses at a discount.
© 2021 Yahoo. All rights reserved.
